{"id":"W4405042974","doi":"10.1182/blood-2024-203269","title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Adverse effect; Internal medicine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00120275,0.0006844133,0.001350387,0.0003044855,0.0001640942,0.0007300858,0.0006246691,0.0007576835,0.001977542],"category_scores_gemma":[0.0009084455,0.0002987401,0.002102132,0.0003747527,0.0004729748,0.0005125021,0.0004718441,0.001546661,0.000293691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009023955,"about_ca_system_score_gemma":0.0007135165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001798387,"about_ca_topic_score_gemma":0.005775683,"domain_scores_codex":[0.9996023,0.0001933093,0.00003165387,0.0000584372,0.00002909712,0.00008529754],"domain_scores_gemma":[0.9992299,0.0001513655,0.000257627,0.00005707802,0.0000237356,0.0002803246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9422798,0.003988589,0.01446778,0.0004700353,0.003974949,0.00006730779,0.0001112411,0.001456218,0.004248167,0.0001278358,0.001065382,0.02774271],"study_design_scores_gemma":[0.581095,0.3431355,0.06223902,0.0001239139,0.006362577,0.0002195995,0.0001304738,0.002126967,0.00185564,0.0004108645,0.002244132,0.00005641991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967214,0.001591138,0.00008289985,0.0001214449,0.00004241328,0.0002595751,0.00067017,0.00001432901,0.0004965799],"genre_scores_gemma":[0.9972091,0.0007118855,0.0002008197,0.0002705978,0.00005336209,0.0003022986,0.0006908001,0.000004964943,0.0005562599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001977542,"threshold_uncertainty_score":0.00661552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01900988019883937,"score_gpt":0.2961543045955663,"score_spread":0.2771444243967269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}